Evaluation of the chemoprotective role of N-acetylcysteine on cisplatin-induced nephrotoxicity: New aspect of an old drug

International Journal of Pharmacology

Volumn 4, Issue 5, 2008, Pages 339-351

  Abdin, Amany A ^a   Draz, Eman I ^a   Sarhan, Naglaa I ^a  

^a TANTA UNIVERSITY   (Egypt)

Author keywords

Apoptosis; Cisplatin; N acetylcysteine; Nephrotoxicity

Indexed keywords

ACETYLCYSTEINE; CASPASE 3; CISPLATIN; CREATININE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL VACUOLE; CHEMOPROPHYLAXIS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DNA FRAGMENTATION; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DRUG TOLERABILITY; ENZYME MECHANISM; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY PROXIMAL TUBULE; NEPHROTOXICITY; NONHUMAN; RAT; RENAL PROTECTION; UREA BLOOD LEVEL;

EID: 63749112275     PISSN: 18117775     EISSN: 18125700     Source Type: Journal    
DOI: 10.3923/ijp.2008.339.351     Document Type: Article

References (88)

1. Aljanabi, S.M. and L. Martinez, 1997. Universal and rapid salt extraction of high quality genomic DNA for PCR based technique. Nucleic Acid Res., 25: 4692-4693.
2. Appenroth, D., K. Winnefeld, H. Schroter and M. Rost, 1993. Beneficial effect of acetylcysteine on cisplatin nephrotoxicity in rats. J. Applied Toxicol., 13: 189-192.
3. Arany, I. and R.L. Safirstein, 2003. Cisplatin nephrotoxicity. Semin Nephrol., 23: 460-464.
4. Bartels, H. and M. Bohmer, 1973. A kinetic method for measurement of creatinine in serum. Med. Lab. Stuttg., 26: 209-215.
5. Basnakian, A.G., G.P. Kaushal and S.V. Shah, 2002. Apoptotic pathways of oxidative damage to renal tubular epithelial cells. Antioxid Redox Signal, 4: 915-924.
6. Blakley, B.W., J.I. Cohen, N.D. Doolittle, L.L. Muldoon, K.C. Campbell, D.T. Dickey and E.A. Neuwelt, 2002. Strategies for prevention of toxicity caused by platinum-based chemotherapy: Review and summary of the annual meeting of the blood-brain barrier disruption program, Gleneden Beach, Oregon, March 10, 2001. The Laryngoscope, 112: 1997-2001.
7. Borgstrom, L., B. Kagedal and O. Paulsen, 1986. Pharmacokinetics of N-acetylcysteine in man. Eur. J. Clin. Pharmacol., 31: 217-217.
8. Borgstrom, L. and B. Kagedal, 1990. Dose dependent pharmacokinetics of N-acetylcysteine after oral dosing to man. Biopharm. Drug Dispos., 11: 131-136.
9. Brivet, F., J.M. Pavlovitch, A. Gouyette, M.L. Cerrina, G. Tchernia and J. Dormont, 1986. Inefficiency of early prophylactic hemodialysis in cis-platinum overdose. Cancer Chemother Pharmacol., 18: 183-184.
10. Chirino, Y.I., R. Hernandez-Pando and J. Pedraza-Chaveri, 2004. Peroxynitrite decomposition catalyst ameliorates renal damage and protein nitration in cisplatin-induced nephrotoxicity in rats. 1. BMC. Pharmacol., 4: 20-29.
11. Choi, B.K., C.H. Choi, H.L. Oh and Y.K. Kim, 2004. Role of ERK activation in cisplatin-induced apoptosis in A172 human glioma cells. Neurotoxicology, 25: 915-924.
12. De Flora, S., A. Izzotti, F. D'Agostini and R.M. Balansky, 2001. Mechanisms of N-acetylcysteine in the prevention of DNA damage and cancer, with special reference to smoking-related end-points. Carcinogenesis, 22: 999-1013.
13. Del Bello, B., M.A. Valentini, P. Mangiavacchi, M. Comporti and E. Maellaro, 2004. Role of caspases-3 and-7 in Apaf-1 proteolytic cleavage and degradation events during cisplatin-induced apoptosis in melanoma cells. Exp. Cell Res., 293: 302-310.
14. Dickey, D.T., Y.J. Wu, L.L. Muldoon and E.A. Neuwelt, 2005. Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular and in vivo levels. J. Pharmacol. Exp. Ther. Q., 314: 1052-1058.
15. Dizdaroglu, M., G. Rao, B. Halliwell and E. Gajewski, 1991. Damage to the DNA bases in mammalian chromatin by hydrogen peroxide in the presence of ferric and cupric ions. Arch Biochem. Biophys., 285: 317-324.
16. Evans, D.L., M. Tilby and C. Dive, 1994. Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation. Cancer Res., 54: 1596-1603.
17. Fawcett, J.K. and J.E. Scott, 1960. A rapid and precise method for the determination of urea. J. Clin. Pathol., 13: 156-159.
18. Fulda, S., C. Scaffidi, T. Pietsch, P.H. Krammer, M.E. Peter and K.M. Debatin, 1998. Activation of the CD95 (APO-1/Fas) pathway in drug- and gamma-irradiation-induced apoptosis of brain tumor cells. Cell Death Differ., 5: 884-893.
19. Gonzalez, V.M., M.A. Fuertes, C. Alonso and J.M. Perez, 2001. Is cisplatin-induced cell death always produced by apoptosis? Mol. Pharmacol., 59: 657-663.
20. Greggi Antunes, L.M., J.D. Darin and M. Bianchi, 2000. Protective effects of vitamin C against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats. Pharmacol. Res., 41: 405-411.
21. Hartmann, J.T. and H.P. Lipp, 2003. Toxicity of platinum compounds. Expert Opin. Pharmacother., 4: 889-901.
22. Hassab El-Nabi, S.E., 2004. Molecular and cytogenic studies on the antimutagenic potential of eugenol in human lymphocytes culture treated with depakine and apetryl drugs. J. Egypt Ger. Soc. Zool., 43c: 171-196.
23. Heidman, H.T., J.F. Gerkens, E.K. Jackson and R.A. Branch, 1985. Attenuation of cisplatin induced nephrotoxicity in the rat by high salt diet, furosemide and acetazolamide. Arch Pharmacol., 329: 201-205.
24. Hermann, H.W., 1970. Chronic human toxicity study of orally administered acetylcysteine. Mead Johnson Research Center Report (Herm-HW-03637) Final Study Report, 1970.
25. Hofmann, G., T. Bauemhofer, P. Krippl, D. Lang-Loidolt, S. Horn, W. Goessler, W. Schippinger, F. Ploner, H. Stoeger and H. Samonigg, 2006. Plasmapheresis reverses all side-effects of a cisplatin overdose-a case report and treatment recommendation. BMC Cancer, 6: 1-1.
26. Holoye, P.Y., J. Dulege, R.M. Hansen, P.S. Ritch and T. Anderson, 1983. Prophylaxis of ifosfamide toxicity with oral acetylcysteine. Semin Oncol., 10: 66-77.
27. Huang, Q., R.T. Dunn, S. Jayadev, O. DiSorbo, F.D. Pack, S.B. Farr, R.E. Stoll and K.T. Blanchard, 2001. Assessment of cisplatin-induced nephrotoxicity by microarray technology. Toxicol. Sci., 63: 196-207.
28. Ishikawa, T. and F. Ali-Osman, 1993. Glutathione-associated cis-diamminedichloroplatinum (II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J. Biol. Chem., 268: 25-29.
29. Johnston, R.E., H.C. Hawkins and J.H. Jr. Weikel, 1983. The toxicity of N-acetylcysteine in laboratory animals. Semin Oncol., 10: 17-24.
30. Johnson, S.W., P.A. Swiggard, L.M. Handel, J.M. Brennan, A.K. Godwin, R.F. Ozols and T.C. Hamilton, 1994. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and-resistant human ovarian cancer cells. Cancer Res., 54: 5911-5916.
31. Karimi, G., M. Ramezani and Z. Tahoonian, 2005. Cisplatin nephrotoxicity and protection by milk thistle extract in rats. Evid Based Comp. Alt. Med., 2: 383-386.
32. Kishimoto, S., Y. Kawazoe, M. Ikeno, S. Fukushima and Y. Takeuchi, 2005. Continuous exposure to low-dose cisplatin and apoptosis. Biol. Pharm. Bull., 28: 1954-1957.
33. Konstantinov, S., M. Topashka-Ancheva, M. Karaivanova, G. Zoneva and I. Galova, 1994. Antitumor, nephrotoxic and clastogenic effect of cis-DDP with DDTC or NAC. Neoplasma, 41: 253-258.
34. Kroning, R., A.K. Lichtenstein and G.T. Nagami, 2000. Sulfur-containing amino acids decrease cisplatin cytotoxicity and uptake in renal tubule epithelial cell lines. Cancer Chemother. Pharmacol., 45: 43-49.
35. Kuhlmann, M.K., G. Burkhardt and H. Köhler, 1997. Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol. Dial. Transplant., 12: 2478-2480.
36. Kurihara, N., T. Kubota, Y. Hoshiya, Y. Otani, K. Kumai and M. Kitajima, 1995. Antitumor activity of cis-diamminedichloroplatinum (II) depends on its time × concentration product against human gastric cancer cell lines in vitro. J. Surg. Oncol., 60: 238-241.
37. Lagrange, J.L., E. Cassuto Viguier, V. Barbe, J.L. Fischel, J.R. Mondain, M.C. Etienne, J.M. Ferrero, A. Creisson-Ducray, P. Formento and G. Milano, 1994. Cytotoxic effects of long-term circulating ultrafiltrable platinum species and limited efficacy of haemodialysis in clearing them. Eur. J. Cancer, 30A: 2057-2060.
38. Leibbrandt, M.E.I., H.I.W. Grushenka, A.L. Metz, A.A. Ozobia and J.R. Haskins, 1995. Critical subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cells. Kidney Int., 48: 761-770.
39. Levin, S., T.J. Buci, S.M. Cohen, A.S. Fix, J.F. Hardisty, E.K. LeGrand, R.R. Maronpot and B.J. Trump, 1999. The nomenclature of cell death: Recommendations of an ad hoc committee of the society of toxicologic pathologists. Toxicol. Pathol., 27: 484-490.
40. Li, Q.Q., M.K. Yunmbam, X. Zhong, J.J. Yu, E.G. Mimnaugh, L. Neckers and E. Reed, 2001. Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression. Cell Mol. Biol., 47: OL61-OL72.
41. Liu, X., P. Li, P. Widlak, H. Zou, X. Luo, W.T. Garrard and X. Wang, 1998. The 40-kDa subunit of DNA fragmentation factor induces DNA fragmentation and chromatin condensation during apoptosis. Proc. Natl. Acad Sci. USA., 95: 8461-8466.
42. Lortholary, O., F.O. Blanchet, D. Nochy, D. Heudes, N. Seta, P. Amirault and C. Carbon, 1993. Effects of diltiazem on netilmicin-induced nephrotoxicity in rabbits. Antimicrob. Agents Chemother., 93: 1790-1798.
43. Ludwig, T. and H. Oberleithner, 2004. Platinum toxicity in cultured renal cells. Cell Physiol. Biochem., 14: 431-440.
44. Markman, M., 2003. Toxicities of the platinum antineoplastic agents. Expert Opin. Drug Saf., 2: 597-607.
45. McEvoy, G.K., 2006. Antineoplastic agents cisplatin. In: AHFS Drug Information. American Society of Health-System Pharmacists, pp: 979-994.
46. Montine, T.J. and R.F. Borch, 1990. Role of endogenous sulfur containing nucleophiles in an in vitro model of cis-diamminedichloroplatinium-induced nephrotoxicity. Biochem. Pharmacol., 39: 1751-1757.
47. Mora, L., L.M. Antunes, H.D. Francescato and M. Bianchi, 2003. The effects of oral glutamine on cisplatin-induced nephrotoxicity in rats. Pharmacol. Res., 47: 517-522.
48. Morazzoni, F., C. Canevali, M. Zucchetti, S. Caroli, A. Alimonti, F. Petrucci, G. Giudice, E. Masoni and A.V. Bedini, 1998. Cis-Diamminedichloroplatinum(II) given in low-dose continuous infusion with concurrent radiotherapy to patients affected by inoperable lung carcinoma: A pharmacokinetic approach. J. Cancer Res. Clin. Oncol., 124: 37-43.
49. Muldoon, L.L., M.A. Pagel, R.A. Kroll, R.E. Brummett, N.D. Doolittle, E.G. Zuhowski, M.J. Egorin and E.A. Neuwelt, 2000. Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity. Clin. Cancer Res., 6: 309-315.
50. Muldoon, L.L., S.L. Walker-Rosenfeld, C. Hale, S.E. Purcell, L.C. Bennett and E.A. Neuwelt, 2001. Rescue from enhanced alkylator-induced cell death with low molecular weight sulfur-containing chemoprotectants. J. Pharmacol. Exp. Med., 296: 797-805.
51. Nagata, S., 2000. Apoptotic DNA fragmentation. Exp. Cell Res., 256: 12-18.
52. Neuwelt, E.A., M.A. Pagel, B.P. Hasler, T.G. Deloughery and L.L. Muldoon, 2001. Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model. Cancer Res., 61: 7868-7874.
53. Neuwelt, E.A., M.A. Pagel, D.F. Kraemer, D.R. Peterson and L.L. Muldoon, 2004. Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. J. Pharmacol. Exp. Ther., 309: 594-599.
54. Ozawa, S., Y. Sugiyama, Y. Mitsuhashi, T. Kobayashi and M. Inaba, 1988. Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration-time product. Cancer Chemother. Pharmacol., 21: 185-190.
55. Papkin, F.B., 1984. Medical Statistics Made Easy. 1st Edn., Churchil Livingstone, Edinburgh, New York, pp: 46-91.
56. Pendyala, L. and P.J. Creaven, 1995. Pharmacokinetic and pharmacodynamic studies of N-acetylcysteine, a potential chemopreventive agent during a phase I trial. Cancer Epidemiol. Biomarkers Prev., 4: 245-251.
57. Previati, M., I. Lanzoni, E. Corbacella, S. Magosso, S. Giuffre, F. Francioso, D. Arcelli, S. Volinia, A. Barbieri, S. Hatzopoulos, S. Capitani and A. Martini, 2004. RNA expression induced by cisplatin in an organ of Corti-derived immortalized cell line. Hear Res., 196: 8-18.
58. Rao, M. and M.M. Rao, 1992. Protective effects of selenomethionine against cisplatin-induced renal toxicity in mice and rats. J. Pharm. Pharmacol., 50: 687-691.
59. Razzaque, M.S., N. Ahsan and T. Taguchi, 2002. Role of apoptosis in fibrogenesis. Nephron, 90: 365-372.
60. Reynolds, J.E.F., 1996a. Cough Suppressants, Expectorants and Mucolytics. In: Martindale. The Extrapharmacopiae. 32nd Edn. Royal Pharmaceutical Society, London, pp: 1060-1062.
61. Reynolds J.E.F., 1996b. Antineoplastic Agents and Immunosuppressants. In: Martindale. The Extrapharmacopiae. 32nd Edn. Royal Pharmaceutical Society, London, pp: 552-554.
62. Sadowitz P.D., B.A. Hubbard, J.C. Dabrowiak, J. Goodisman, K.A. Tacka, M.K. Aktas, M.J. Cunningham, R.L. Dubowy and A. Souid, 2002. Kinetics of Cisplatin Binding to Cellular DNA and Modulations by Thiol-Blocking Agents and Thiol Drugs. Drug Metab. Dispos., 30: 183-190.
63. Safirstein, R. L. Andrade and J.M. Vierira, 2000. Acetylcysteine and nephrotoxic effects of radiographic contrast agents-a new use for an old drug. N. Eng. J. Med., 343: 210-212.
64. Schuler, M., E. Bossy-Wetzel, J.C. Goldstein, P. Fitzgerald and G.R. Green, 2000. p53 induces apoptosis by caspase activation through mitochondrial cytochrome C release. J. Biol. Chem., 275: 7337-7342.
65. Seki, K., H. Yoshikawa, K. Shiiki, Y. Hamada, N. Akamatsu and K. Tasaka, 2000. Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma. Cancer Chemother. Pharmacol., 45: 199-206.
66. Senturker, S., R. Tschirret-Guth, J. Morrow, R. Levine and E. Shacter, 2002. Induction of apoptosis by chemotherapeutic drugs without generation of reactive oxygen species. Arch Biochem. Biophys., 397: 262-272.
67. Shellard, S.A., A.M. Fichtinger-Schepman, J.S. Lazo and B.T. Hill, 1993. Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines. Anticancer Drugs, 4: 491-500.
68. Shimeda, Y., Y. Hirotani, Y. Akimoto, K. Shindou, Y. Ijiri, T. Nishihori and K. Tanaka, 2005. Protective effects of capsaicin against cisplatin-induced nephrotoxicity in rats. Biol. Pharm. Bull., 28: 1635-1638.
69. Shyu, K.G., J.J. Cheng and P. Kuan, 2002. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J. Am. Coll. Cardiol., 40: 1383-1388.
70. Siddik, Z.H., 2003. Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene, 22: 7265-7279.
71. Silverberg, S.G., R.A. Delellis, W.J. Frable, V.A. Livolsi and M.R. Wick, 2006. Silverberg's Principles and Practice of Surgical Pathology and Cytopathology. Churchill Living Stone, Elseiver, pp: 30.
72. Sprong, R.C., A.M. Winkelhuyzen-Janssen, C.J. Aarsman, J.F. van Oirschot, T. van der Bruggen and B.S. van Asbeck, 1998. Low-dose N-acetylcysteine protects rats against endotoxin-mediated oxidative stress, but high-dose increases mortality. Am. J. Resp. Crit. Care Med., 157: 1283-1293.
73. Sugihara, K., S. Nakano, M. Koda, K. Tanaka, N. Fukuishi and M. Gemba, 1987. Stimulatory effect of cisplatin on production of lipid peroxidation in renal tissues. Jap. J. Pharmacol., 43: 247-252.
74. Sun, X.M., M. MacFarlane, J. Zhuang, B.B. Wolf, D.R. Green and G.M. Cohen, 1999. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J. Biol. Chem., 247: 5053-5060.
75. Tacka, K.A., D. Szalda, A.K. Souid, J. Goodisman and J.C. Dabrowiak, 2004. Experimental and theoretical studies on the pharmacodynamics of cisplatin in jurkat cells. Chem. Res. Toxicol., 17: 1434-1444.
76. Tepel, M., M. van der Giet, C. Schwarzfeld, U. Laufer, D. Liermann and W. Zidek, 2000. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N. Engl. J. Med., 343: 180-184.
77. Townsend, D.M., J.A. Marto, M. Deng, T.J. Macdonald and M.H. Hanigan, 2003. High pressure liquid chromatography and mass spectrometry characterization of the nephrotoxic biotrans formation products of cisplatin. Drug Metab. Dispos., 31: 705-713.
78. Vadoud-Seyedi, J., G. de Dobbeleer and T. Simonart, 2000. Treatment of haemodialysis-associated pseudoporphyria with N-acetylcysteine: Report of two cases. Br. J. Dermatol., 142: 580-581.
79. Widlak, P., 2000. The DFF40/CAD endonuclease and its role in apoptosis. Acta Biochim. Pol., 47: 1037-1044.
80. Wu, Y.J., L.L. Muldoon and E.A. Neuwelt, 2005. The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. J. Pharmacol. Exp. Ther., 312: 424-431.
81. Xiao, T., S. Choudhary, W. Zhang, N.H. Ansari and A. Salahudeen, 2003. Possible involvement of oxidative stress in cisplatin-induced apoptosis in LLC-PK1 cells. J. Toxicol. Environ. Health, 66: 469-479.
82. Yang, Z., L.M. Schumaker, M.J. Egorin, E.G. Zuhowski, Z. Guo and K.J. Cullen, 2006. Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein the mitochondrial membrane of head and neck squamous cell carcinoma: Possible role in apoptosis. Clin. Cancer Res., 12: 5817-5825.
83. Yim, C., J.B. Hibbs, J.R. McGregor, R.E. Galinsky and W.E. Samiowski, 1994. Use of N-acetyl cysteine to increase Intracellular glutathione during the induction of antitumor responses by IL-2. J. Immunol., 152: 5796-5805.
84. Zafarullah, M., W.Q. Li, J. Sylvester and M. Ahmad, 2003. Molecular mechanisms of N-acetylcysteine actions. Cell Mol. Life Sci., 60: 6-20.
85. Zhan, Y., B. van de Water, Y. Wang and J.L. Stevens, 1999. The roles of caspase-3 and bcl-2 in chemically-induced apoptosis but not necrosis of renal epithelial cells. Oncogene, 18: 6502-6512.
86. Zhang, K., P. Mack and K.P. Wong, 1998. Glutathione-related mechanisms in cellular resistance to anticancer drugs. Int. J. Oncol., 12: 871-882.
87. Ziemann, C., A. Bürkle, G.F. Kahl and K.I. Hirsch-Ernst, 1999. Reactive oxygen species participate in mdr1 b mRNA and P-glycoprotein overexpression in primary rat hepatocytes cultures. Carcinogenesis, 20: 407-414.
88. Zunino, F., G. Pratesi, A. Micheloni, E. Cavaletti, F. Sala and O. Tofanetti, 1989. Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug. Chem. Biol. Interact., 70: 89-101.